FDA Delays KalVista’s Sebetralstat Decision Amid Workload Strain

KalVista Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has extended its review of sebetralstat, an investigational treatment for hereditary angioedema (HAE), due to internal workload challenges and resource limitations. The regulatory decision, originally expected by June 17, is now anticipated within the next four weeks.

Sebetralstat, if approved, would become the first oral on-demand therapy for HAE, a rare and potentially life-threatening genetic condition marked by recurrent episodes of severe swelling in areas such as the skin, gastrointestinal tract, and airways. The disorder is caused by a deficiency of the C1 inhibitor protein, and current treatments are primarily injectable.

The FDA has not requested any additional data or clinical studies, nor has it raised concerns about the safety, efficacy, or approvability of the drug. KalVista stated it had responded to all previous information requests promptly and believes the final review is focused solely on the drug’s packaging insert.

This delay is part of a broader pattern of missed FDA deadlines, reportedly linked to widespread staff reductions following restructuring under U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. Despite the delay, KalVista remains optimistic, expressing confidence in the near-term approval of sebetralstat.

The approval of an oral HAE treatment would mark a major milestone in rare disease therapeutics, offering patients a more convenient and accessible alternative to current injectable options.

KalVista’s stock and investor sentiment may hinge on the final FDA decision, with anticipation building for what could be a groundbreaking advancement in hereditary angioedema care. The company reiterated its commitment to bringing sebetralstat to market swiftly once approval is granted.